HOME | ABOUT | VIDEO INDEX | SPONSORS | CREDITS | CONTACT | HELP Skip to content
 | Accessibility Feedback


Search the MIT World Video Archive.

 
 
 

 
 
 
 
HOST:
Technology Review



SERIES:
The Emerging Technologies Conference at MIT (2004)




More videos in this series


From Lab to Market: Where Technology is Headed—The Research Director’s Point of View
September 29, 2004
9:45AM

LOCATION:
Kresge Auditorium



   
Video Time Index
From Lab to Market: Where Technology is Headed—The Research Director’s Point of View

 Play Now | Email to a Friend

MODERATOR:
Rebecca Henderson, ‘81
Eastman Kodak LFM Professor, MIT Sloan School


MODERATOR: Rebecca Henderson, ‘81
Henderson's home page

PANELISTS:
Paul Horn: Senior Vice President and Director
IBM Research
Horn's IBM website

Uma Chowdhry, PhD ‘76: Vice President, Global Central Research and Development
DuPont
Chowdhry's DuPont website

Robert Tepper: President, Research and Development
Millennium Pharmaceuticals
Tepper's Millennium website

ABOUT THE PANEL DISCUSSION:
How do you conduct R&D in a vanguard technology? These three panelists provide varying perspectives on the question. Paul Horn stands by IBM’s longstanding commitment to its 5.5 billion dollar annual research effort, but with some caveats: “It’s all about the speed of flowing new ideas into hardware, software and services,” he says. You can’t think about innovation without also considering “channels to market.” IBM insists that “researchers spend time in the marketplace so they can understand how their technology can solve real world problems.”

At DuPont, Uma Chowdhry cites a “quietly occurring transformation in the area of biobased materials.” At two centuries’ young, DuPont has a new primary challenge: “How do we transform from a petroleum-based economy to renewable resources such as crops?” Working with partners such as MIT, the company is exploring glucose, methane and nanotechnology to cook up new kinds of fuel, food supplements, and other products—all economically. It’s “a very big dream,” acknowledges Chowdhry. The prerequisite, she says, is that “top management must have an unwavering commitment to the mission as well as time, vision and patience.”

Robert Tepper describes the convergence of two revolutions driving his field forward. The complete sequencing of the human genome, combined with advances in understanding pathways of disease, will enable Millennium’s researchers to create “breakthrough therapies.” Scientists are already “making strides in cancer and inflammation,” says Tepper. Millennium is linking up with industry, hospitals and academia, plumbing the genome to learn “why individuals are susceptible to disease.”

NOTES ON THE VIDEO (Time Index):
Video Length is 1:14:56.

Robert Buderi, Editor at Large, Technology Review, introduces the event.

At 1:54, Rebecca Henderson introduces the panel.

At 2:48, Paul Horn begins.

At 12:03, Uma Chowdhry begins.

At 23:50, Bob Tepper begins.

At 34:03, Rebecca Henderson opens up Q&A.

The information on this page was accurate as of the day the video was added to MIT World. This video was added to MIT World on 2004-12-08.
       

MIT: University Home | MIT World Home | About MIT World | Video Index | Help | Sponsors
Site Credits | Contact Us | Register to receive email updates